跳至主要内容
临床试验/NCT05935787
NCT05935787已完成3 期

A Multicenter, Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Sequential Therapy With CYTOFLAVIN® (NTFF POLYSAN, Russia), Solution for Intravenous Infusion and Enteric-coated Tablets, in the Complex Rehabilitation of Patients With Acute Stroke

POLYSAN Scientific & Technological Pharmaceutical Company6 个研究点 分布在 2 个国家目标入组 240 人开始时间: 2023年6月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
240
试验地点
6
主要终点
Change of performance

研究概览

简要总结

It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic acids. Antioxidants may have a positive effect on the processes of reparation, remodeling and neuroplasticity, thus improving the effectiveness of post-stroke rehabilitation. The adjunctive use of drug therapy that improves neuroplasticity may promote accelerated motor learning, which underlies the effects of exercise therapy and physical therapy, speech therapy, and sessions with a psychologist or occupational therapist. CYTOFLAVIN® is a combination of succinic acid, riboflavin, nicotinamide and inosine (riboxin) which has antihypoxic and antioxidant effects. The study hypothetizes that this neurometabolic drug will facilitate learning in stroke survivors and help to acquire new cognitive or motor skills necessary for daily living. The study will be conducted in two parallel groups of stroke survivors: the experimental group will be treated with Cytoflavin along with ohysical rehabilitation, the control group will receive standard rehabilitation course.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed Patient informed consent form
  • Men and women aged 40 to 80, inclusive.
  • Ischemic stroke in the carotid area, or hemorrhagic stroke in the cerebral hemispheres, occurred in the previous 14-90 days before screening.
  • Acute neuroimaging data (CT and/or MRI) do not contradict the clinical and topical diagnosis of stroke.
  • The presence of a measurable neurological deficit in the motor or sensory area.
  • Availability of rehabilitation potential, which is assessed by the specialists of the multidisciplinary team
  • Modified Rankin score 3-
  • The possibility to visit outpatient rehabilitation at the research center.
  • Ability to understand and comply with protocol requirements.
  • For women: consent to use reliable methods of contraception or absent reproductive potential.
  • For men: consent to the use of adequate methods of contraception, or complete abstinence from sexual activity for the period of the study, or absent reproductive potential.

排除标准

  • Known hypersensitivity to any component of the study drug
  • Severe visual and hearing impairments that prevent the implementation of study procedures.
  • Severe spasticity (scored 3-4 by Ashworth scale).
  • Impaired swallowing, which does not allow taking drugs orally.
  • Communication deficit that does not allow the patient to fulfill the conditions of the study protocol (including total aphasia).
  • The presence of contraindications to complex rehabilitation in a hospital (lack of rehabilitation potential, somatic diseases that prevent a complex of rehabilitation measures).
  • Aneurysmal subarachnoid hemorrhage.
  • Previous (before the actual ictus) stroke with residual neurological deficit.
  • Disability is primarily not attributed to the last stroke
  • Severe renal failure
  • Severe liver failure
  • End stage of other chronic incurable diseases.
  • Decompensated diabetes mellitus.
  • History of cancer, mental illness, HIV infection, syphilis, tuberculosis, alcohol, drug or drug addiction.
  • Established diagnosis of a mental or neurodegenerative disease
  • Constant use of psychotropic drugs (neuroleptics, tranquilizers, antidepressants) or nootropic drugs in the previous 3 months before the patient was included in the study, except for stroke treatment in acute hospital.
  • Alcohol or drug addiction
  • 19. Pregnancy, lactation.

研究组 & 干预措施

Cytoflavin

Experimental

干预措施: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid) (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Change of performance

时间窗: 40 days

Change at the performance subscale (range 0-10, higher=better) of Canadian Occupational Performance Measure (COPM) score after completion of therapy compared to baseline

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Cytoflavin in the Complex Rehabilitation of Stroke... | 临床试验